Patient specific modelling of gene regulatory networks and association to clinical characteristics in Alzheimer’s disease

Alzheimer’s Disease (AD) is the most common form of dementia. It leads to increasing problems with memory, thinking and behavior and is a deadly disorder. It is a heterogeneous condition and it is unclear what causes the wide variety of symptoms, therefore there are currently no sufficient treatment options available. It has become increasingly clear that treatment needs to be personalized, to give the right therapy to the right person at the right time-point. Gene regulatory networks, which are complex mechanisms that steer a cell’s function, are likely disrupted in AD, but it is not completely understood how. In aim 1 of this project we will use computational tools to investigate and compare gene regulatory networks in brain tissues of patients with AD and healthy people. In aim 2 we will analyze the networks of individual patients to understand how alike they are, and which characteristics may contribute to AD heterogeneity. In aim 3 we will analyze how groups of genes that work closely together are disrupted in AD, and will identify the most central genes in these groups. This will potentially indicate new treatments and personalized therapy strategies for AD patients.

TSD

  • Nei
  • Begrunnelse: We are currently only working with non sensitive data

Biobank

  • Nei

Godkjenninger

REK - Ja 1 fil

Disse dokumentene er kun synlige for prosjektleder, enhetens leder og forskningsadministrasjon.

Prosjektleder / prosjektansvarlig ved UiO

Marieke Kuijjer

Ansvarlig enhet

Norsk Senter for Molekylærmedisin

Forskere

  • Annikka Virginia Polster
  • Kimberly Glass (Harvard Medical School)
  • Laxmi Parida (IBM Research)
  • Henrik Zetterberg (Göteborgs Universitet)

Prosjekttype

  • Forskerprosjekt

Helsefaglig forskning

  • Ja

Personopplysninger

  • Nei

Tidsperiode

  • Start: februar 2020
  • Slutt: desember 2025